Freely accessible research on castration resistant prostate cancer
20.09.2015
ADVANCED PROSTATE CANCER RESOURCE CENTRE

Latest developments for uro-oncologist in the management of castration resistant prostate cancer

Welcome to the European Urology Advanced Prostate Cancer Resource Centre! The resource centre is freely accessible and it is our goal to inform you with the latest developments in the management of castration resistant prostate cancer.

To stay informed of new research and guidelines on this Resource Centre you can register for our email-alert.

You can visit the Resource Centre now or access this month's selected key content below.

Full text articles

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
Klaus Brasso, Frederik B. Thomsen, Andres J. Schrader, Sebastian C. Schmid, David Lorente, Margitta Retz, Axel S. Merseburger, Christoph A. von Klot, Martin Boegemann, Johann de Bono
European Urology 2015 Aug;68(2):317-24

The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullura, Ottavio De Cobelli, Franco Nole 
European Journal of Cancer, Volume 51, Issue 14, September 2015, Pages 1970 - 1977

Key Publications

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL) 
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al.
Lancet Oncol. 2015 May;16(5):509-21

Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279) 
Bahl A, Masson S, Malik Z, Birtle AJ, Sundar S, Jones RJ, et al.
BJU International 2015 Jan 30. [Epub ahead of print]

Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
Shigeta K, Kosaka T, Yazawa S, Yasumizu Y, Mizuno R, Nagata H, et al.
Int J Clin Oncol. 2015 Jun;20(3):605-12

Efficacy and toxicity of anti-VEGF agents in patients with castration-resistant prostate cancer: a meta-analysis of prospective clinical studies
Qi W-X, Fu S, Zhang Q, Guo X-M.
Asian Pac J Cancer Prev. 2014;15(19):8177-82

 

Editor's Choice of Clinical Trial Studies

Here you can find a list with the latest clinical trials and press releases published on the platform.

 

  • Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
  • Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
  • A Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC

 

Made possible by an educational grant from Janssen
Elsevier

This message has been sent to Этот адрес e-mail защищен от спам-ботов. Чтобы увидеть его, у Вас должен быть включен Java-Script from Elsevier Communications on behalf of Elsevier Healthcare.
If you no longer wish to receive messages of this nature from us in the future, please click here.
Visit the Elsevier Preference Center to manage more of your communication preferences with us. 
Copyright © 2015 Elsevier B.V.. All rights reserved. | Elsevier Privacy Policy 
Elsevier B.V. Registered Office: Radarweg 29, 1043 NX Amsterdam, The Netherlands. Reg. No. 33158992 – Netherlands. VAT No. NL 005033019B01.